Javier, Cortes, MD, PhD IOB Italy Institute of Oncology Quiron Group Madrid and Barcelona, Spain 5Live #ASCO20
5:10
Key Insights on KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemo vs placebo + chemo for previously untreated locally recurrent inoperable or metastatic TNBC
Key Insights on KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemo vs placebo + chemo for previously untreated locally recurrent inoperable or metastatic TNBC
Breast Cancer Similar Videos
-
Podium to Practice: Recent Updates on the Treatment of Breast Cancer from the 2021 San Antonio Breast Cancer Annual Meeting_Sara Hurvitz, MD, FACP_Sara Tolaney, MD, MPH
38:09
-
Harnessing the Power of Antibody-Drug Conjugates for the Treatment of Hematologic and Solid Cancer: Leveraging Antibody-Drug Conjugates in Breast Cancer Care_Hope Rugo, MD, FASCO
53:15
-
Mylin Torres, MD; Emory University Winship Cancer Institute; #DDHO2022
19:43